Seroprevalence of anti-SARS-CoV-2 IgG antibodies among vaccinated healthcare workers in Bamako, Mali
Etienne Dembele, Yacouba Cissoko, Anou M Somboro, Aichata Dembele, Josue Togo, Djibril M Bah, Issiaka Camara, Ousmane Kodio, Mohamed Tolofoudie, Bourahima Kone, Antieme CG Togo, Bocar Baya, Bassirou Diarra, Yeya Dit Sadio Sarro, Robert L Murphy, Almoustapha I Maiga, Jane L Holl

TL;DR
This study measured anti-SARS-CoV-2 antibodies in vaccinated healthcare workers in Mali to assess vaccine effectiveness.
Contribution
The study provides empirical evidence on vaccine-induced antibody responses in a low-resource setting.
Findings
98.2% of vaccinated healthcare workers had high anti-SARS-CoV-2 IgG antibody levels.
Two-dose vaccine recipients had significantly higher antibody levels than one-dose recipients.
Astra Zeneca® was the most widely used vaccine, with 52.3% of participants receiving it.
Abstract
Like many other countries, Mali, a West African country, has encountered various obstacles in the fight against the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite resource constraints, however, the country implemented containment strategies. Therefore, in early 2021, Mali initiated a vaccination campaign as a tangible defense against COVID-19, prioritizing the administration of the first vaccine doses to healthcare personnel. Consequently, we found assessing anti-SARS-CoV-2 IgG antibody levels important to gauge the efficacy of vaccines administered to frontline healthcare workers in Bamako, Mali. The study enrolled 172 vaccinated front-line healthcare workers from referral hospitals in Bamako, Mali, between March and June 2022. Serum samples were subjected to enzyme-linked immunosorbent assay (ELISA) to assess the levels of anti-SARS-CoV-2 IgG…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · vaccines and immunoinformatics approaches
